These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 25886189)

  • 1. Posttranslational modification and mutation of histidine 50 trigger alpha synuclein aggregation and toxicity.
    Xiang W; Menges S; Schlachetzki JC; Meixner H; Hoffmann AC; Schlötzer-Schrehardt U; Becker CM; Winkler J; Klucken J
    Mol Neurodegener; 2015 Mar; 10():8. PubMed ID: 25886189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
    Lima VA; do Nascimento LA; Eliezer D; Follmer C
    ACS Chem Neurosci; 2019 Jan; 10(1):690-703. PubMed ID: 30352158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Environmental and genetic factors support the dissociation between α-synuclein aggregation and toxicity.
    Villar-Piqué A; Lopes da Fonseca T; Sant'Anna R; Szegö ÉM; Fonseca-Ornelas L; Pinho R; Carija A; Gerhardt E; Masaracchia C; Abad Gonzalez E; Rossetti G; Carloni P; Fernández CO; Foguel D; Milosevic I; Zweckstetter M; Ventura S; Outeiro TF
    Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6506-E6515. PubMed ID: 27708160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative stress-induced posttranslational modifications of alpha-synuclein: specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity.
    Xiang W; Schlachetzki JC; Helling S; Bussmann JC; Berlinghof M; Schäffer TE; Marcus K; Winkler J; Klucken J; Becker CM
    Mol Cell Neurosci; 2013 May; 54():71-83. PubMed ID: 23369945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation.
    Lázaro DF; Rodrigues EF; Langohr R; Shahpasandzadeh H; Ribeiro T; Guerreiro P; Gerhardt E; Kröhnert K; Klucken J; Pereira MD; Popova B; Kruse N; Mollenhauer B; Rizzoli SO; Braus GH; Danzer KM; Outeiro TF
    PLoS Genet; 2014 Nov; 10(11):e1004741. PubMed ID: 25393002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein.
    Rutherford NJ; Moore BD; Golde TE; Giasson BI
    J Neurochem; 2014 Dec; 131(6):859-67. PubMed ID: 24984882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha synuclein dimers and oligomers are increased in overexpressing conditions in vitro and in vivo.
    Marmolino D; Foerch P; Atienzar FA; Staelens L; Michel A; Scheller D
    Mol Cell Neurosci; 2016 Mar; 71():92-101. PubMed ID: 26711807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-terminal acetylation mutants affect alpha-synuclein stability, protein levels and neuronal toxicity.
    Vinueza-Gavilanes R; Íñigo-Marco I; Larrea L; Lasa M; Carte B; Santamaría E; Fernández-Irigoyen J; Bugallo R; Aragón T; Aldabe R; Arrasate M
    Neurobiol Dis; 2020 Apr; 137():104781. PubMed ID: 31991248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico analysis of alpha-synuclein protein variants and posttranslational modifications related to Parkinson's disease.
    da Silva ANR; Pereira GRC; Bonet LFS; Outeiro TF; De Mesquita JF
    J Cell Biochem; 2024 Mar; 125(3):e30523. PubMed ID: 38239037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The H50Q mutation enhances α-synuclein aggregation, secretion, and toxicity.
    Khalaf O; Fauvet B; Oueslati A; Dikiy I; Mahul-Mellier AL; Ruggeri FS; Mbefo MK; Vercruysse F; Dietler G; Lee SJ; Eliezer D; Lashuel HA
    J Biol Chem; 2014 Aug; 289(32):21856-76. PubMed ID: 24936070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different Effects of α-Synuclein Mutants on Lipid Binding and Aggregation Detected by Single Molecule Fluorescence Spectroscopy and ThT Fluorescence-Based Measurements.
    Ruf VC; Nübling GS; Willikens S; Shi S; Schmidt F; Levin J; Bötzel K; Kamp F; Giese A
    ACS Chem Neurosci; 2019 Mar; 10(3):1649-1659. PubMed ID: 30605594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the role of methionine residues on the oligomerization and neurotoxic properties of DOPAL-modified α-synuclein.
    Carmo-Gonçalves P; do Nascimento LA; Cortines JR; Eliezer D; Romão L; Follmer C
    Biochem Biophys Res Commun; 2018 Oct; 505(1):295-301. PubMed ID: 30249394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation.
    Lázaro DF; Dias MC; Carija A; Navarro S; Madaleno CS; Tenreiro S; Ventura S; Outeiro TF
    Acta Neuropathol Commun; 2016 Dec; 4(1):128. PubMed ID: 27938414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E46K α-synuclein pathological mutation causes cell-autonomous toxicity without altering protein turnover or aggregation.
    Íñigo-Marco I; Valencia M; Larrea L; Bugallo R; Martínez-Goikoetxea M; Zuriguel I; Arrasate M
    Proc Natl Acad Sci U S A; 2017 Sep; 114(39):E8274-E8283. PubMed ID: 28900007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Traffic jams and the complex role of α-Synuclein aggregation in Parkinson disease.
    Gonçalves SA; Outeiro TF
    Small GTPases; 2017 Apr; 8(2):78-84. PubMed ID: 27314512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential direct role of synuclein in dopamine transport and its implications for Parkinson's disease pathogenesis.
    Kim M; Bezprozvanny I
    Biochem Biophys Res Commun; 2023 Sep; 671():18-25. PubMed ID: 37290280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers.
    Dokleja L; Hannula MJ; Myöhänen TT
    Neurosci Lett; 2014 Nov; 583():37-42. PubMed ID: 25240592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α-synuclein.
    Wang W; Nguyen LT; Burlak C; Chegini F; Guo F; Chataway T; Ju S; Fisher OS; Miller DW; Datta D; Wu F; Wu CX; Landeru A; Wells JA; Cookson MR; Boxer MB; Thomas CJ; Gai WP; Ringe D; Petsko GA; Hoang QQ
    Proc Natl Acad Sci U S A; 2016 Aug; 113(34):9587-92. PubMed ID: 27482083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease.
    Zondler L; Miller-Fleming L; Repici M; Gonçalves S; Tenreiro S; Rosado-Ramos R; Betzer C; Straatman KR; Jensen PH; Giorgini F; Outeiro TF
    Cell Death Dis; 2014 Jul; 5(7):e1350. PubMed ID: 25058424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation.
    Qin Z; Hu D; Han S; Reaney SH; Di Monte DA; Fink AL
    J Biol Chem; 2007 Feb; 282(8):5862-70. PubMed ID: 17189262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.